...
首页> 外文期刊>Neurotoxicology >Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: Mitochondrial dysfunction and neurodegeneration
【24h】

Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: Mitochondrial dysfunction and neurodegeneration

机译:蛋白酶抑制剂在3-硝基丙酸诱导的亨廷顿舞蹈病中的潜力,例如症状:线粒体功能障碍和神经变性

获取原文
获取原文并翻译 | 示例
           

摘要

Huntington's disease (HD) is a genetic, neurodegenerative disorder mainly characterized by motor dysfunction, cognitive decline and psychiatric disturbances. 3-Nitropropionic acid (3-NP) is an inhibitor of succinate dehydrogenase (Complex II) of the mitochondrial respiratory chain, which thereby reduces production of ATP. It induces neurotoxicity by causing striatal degeneration, energy deficit and oxidative stress. Angiotensin converting enzyme (ACE) is an important protease in the renin angiotensin system (RAS) responsible for the conversion of Angiotensin I to Angiotensin II. Angiotensin-II stimulates mitochondrial oxidant release leading to depression of energy metabolism. ACE inhibitors have shown promise in disorders like stress, anxiety, and depression in addition to showing beneficial effects in cognitive disorders like Alzheimer's. Angiotensin-II inhibition enhances energy production by lowering mitochondrial oxidant production, and hence protects mitochondrial structure. Trandolapril is a centrally active ACE inhibitor. 3-NP administered systematically (20 mg/kg, i.p) for 4 days consecutively induced HD like symptoms - loss of body weight, neurobehavioral alterations like memory dysfunction (elevated plus maze, Morris water maze performance), Hind-limb impairment (Narrow beam test), motor incoordination (locomotor activity). Biochemical studies on brain tissue showed increased lipid peroxidation, nitrite levels and acetylcholinesterase activity along with decreased levels of reduced glutathione, catalase activity. Mitochondrial enzyme complex activities (I, II, IV and MTT assay) were found to be significantly lowered in brain mitochondria. Administration of Trandolapril (4 and 6 mg/kg, p.o) daily for 12 days showed significant improvement in body weight, neurobehavioral parameters, oxidative stress and mitochondrial enzyme activities in rat brain. These findings were further confirmed by histopathological studies which showed improvement in 3-NP induced brain lesions. This study indicates that Trandolapril could be an effective treatment option for the management of HD. (C) 2014 Elsevier Inc. All rights reserved.
机译:亨廷顿舞蹈病(HD)是一种遗传性神经退行性疾病,主要特征在于运动功能障碍,认知能力下降和精神疾病。 3-硝基丙酸(3-NP)是线粒体呼吸链琥珀酸脱氢酶(复合物II)的抑制剂,从而减少了ATP的产生。它通过引起纹状体变性,能量缺乏和氧化应激来诱导神经毒性。血管紧张素转化酶(ACE)是肾素血管紧张素系统(RAS)中的重要蛋白酶,负责将血管紧张素I转化为血管紧张素II。血管紧张素II刺激线粒体氧化剂释放,导致能量代谢下降。 ACE抑制剂除了对阿尔茨海默氏症等认知障碍具有有益作用外,还显示出在压力,焦虑和抑郁等疾病中的前景。血管紧张素-II抑制通过降低线粒体氧化剂的产生来增强能量产生,从而保护线粒体的结构。 Trandolapril是一种中枢活性ACE抑制剂。连续4天系统性给予3-NP(20 mg / kg,ip)诱发HD症状-体重减轻,神经行为改变如记忆障碍(高迷宫,莫里斯水迷宫表现),后肢损伤(窄束)测试),运动不协调(运动活动)。对脑组织的生化研究表明,脂质过氧化作用增加,亚硝酸盐水平和乙酰胆碱酯酶活性升高,而谷胱甘肽,过氧化氢酶活性降低水平降低。发现线粒体酶复合物活性(I,II,IV和MTT分析)在脑线粒体中显着降低。每天服用Trandolapril(4和6 mg / kg,p.o)持续12天,显示大鼠大脑的体重,神经行为参数,氧化应激和线粒体酶活性显着改善。这些发现被组织病理学研究进一步证实,该研究表明3-NP诱导的脑损伤有所改善。这项研究表明,Trandolapril可能是HD的有效治疗选择。 (C)2014 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号